{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:33:03Z","timestamp":1792805583723,"version":"4.5.0"},"reference-count":157,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023-MHLS-286"],"award-info":[{"award-number":["2023-MHLS-286"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014717","name":"National Natural Science Foundation of China National Outstanding Youth Science Fund Project","doi-asserted-by":"publisher","award":["82204685"],"award-info":[{"award-number":["82204685"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007620","name":"Department of Education of Liaoning Province","doi-asserted-by":"publisher","award":["LJKMZ20221795"],"award-info":[{"award-number":["LJKMZ20221795"]}],"id":[{"id":"10.13039\/501100007620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010086","name":"Foundation of Liaoning Province Education Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bbcan.2025.189386","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:47:28Z","timestamp":1752587248000},"page":"189386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Key subunits of \u03b3-secretase complex and breast cancer progression: biological function, regulation mode and therapeutic potential"],"prefix":"10.1016","volume":"1880","author":[{"given":"Ran","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Zhi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Yi","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(18)30083-4","article-title":"Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force\/Breast Cancer Group","volume":"19","author":"Wildiers","year":"2018","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189386_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-024-01649-z","article-title":"Current and future immunotherapy for breast cancer","volume":"17","author":"Heater","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2025.189386_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314937","article-title":"Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer","volume":"23","author":"Kudelova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189386_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2019.07.012","article-title":"Notch signaling in breast cancer: from pathway analysis to therapy","volume":"461","author":"Krishna","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189386_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115991","article-title":"Inhibition of \u03b3-secretase\/Notch pathway as a potential therapy for reversing cancer drug resistance","volume":"220","author":"Feng","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189386_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116296","article-title":"Notch signaling in breast tumor microenvironment as mediator of drug resistance","volume":"23","author":"Chimento","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1535-7163.MCT-10-0677","article-title":"Notch signaling pathway as a therapeutic target in breast cancer","volume":"10","author":"Al-Hussaini","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0050","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1038\/s41467-024-48776-2","article-title":"Apo and A\u03b246-bound \u03b3-secretase structures provide insights into amyloid-\u03b2 processing by the APH-1B isoform","volume":"15","author":"Odor\u010di\u0107","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0055","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4103\/NRR.NRR-D-23-01781","article-title":"Emerging structures and dynamic mechanisms of \u03b3-secretase for Alzheimer\u2019s disease","volume":"20","author":"Miao","year":"2025","journal-title":"Neural Regen. Res."},{"issue":"6700","key":"10.1016\/j.bbcan.2025.189386_bb0060","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1126\/science.adn5820","article-title":"Molecular mechanism of substrate recognition and cleavage by human \u03b3-secretase","volume":"384","author":"Guo","year":"2024","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189386_bb0065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024067","article-title":"Structural and chemical biology of presenilin complexes","volume":"7","author":"Johnson","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bbcan.2025.189386_bb0070","doi-asserted-by":"crossref","first-page":"19522","DOI":"10.1038\/srep19522","article-title":"Structure of the transmembrane domain of human nicastrin-a component of \u03b3-secretase","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2025.189386_bb0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1750-1326-9-59","article-title":"Structural biology of presenilin 1 complexes","volume":"9","author":"Li","year":"2014","journal-title":"Mol. Neurodegener."},{"issue":"7430","key":"10.1016\/j.bbcan.2025.189386_bb0080","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nature11801","article-title":"Structure of a presenilin family intramembrane aspartate protease","volume":"493","author":"Li","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189386_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074383","article-title":"The structure of neuronal calcium sensor-1 in solution revealed by molecular dynamics simulations","volume":"8","author":"Bellucci","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0896-6273(03)00205-8","article-title":"Aph-1, pen-2, and Nicastrin with Presenilin generate an active gamma-secretase complex","volume":"38","author":"De Strooper","year":"2003","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0095","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006304","article-title":"Presenilins and \u03b3-secretase: structure, function, and role in Alzheimer disease","volume":"2","author":"De Strooper","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189386_bb0100","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1074\/jbc.M310505200","article-title":"Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the gamma-secretase complex","volume":"279","author":"Fortna","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189386_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810970","article-title":"Genetics, functions, and clinical impact of Presenilin-1 (PSEN1) gene","volume":"23","author":"Bagaria","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189386_bb0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.semcdb.2020.02.006","article-title":"Structure-activity relationship of presenilin in \u03b3-secretase-mediated intramembrane cleavage","volume":"105","author":"Cai","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0115","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1038\/s41467-024-48151-1","article-title":"Structural basis for the intracellular regulation of ferritin degradation","volume":"15","author":"Hoelzgen","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031757","article-title":"Presenilin: a multi-functional molecule in the pathogenesis of Alzheimer\u2019s disease and other neurodegenerative diseases","volume":"25","author":"Sun","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189386_bb0125","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1523\/JNEUROSCI.2523-18.2019","article-title":"Conditional inactivation of pen-2 in the developing neocortex leads to rapid switch of apical progenitors to basal progenitors","volume":"39","author":"Cheng","year":"2019","journal-title":"J. Neurosci."},{"issue":"37","key":"10.1016\/j.bbcan.2025.189386_bb0130","doi-asserted-by":"crossref","first-page":"13349","DOI":"10.1073\/pnas.1414837111","article-title":"Crystal structure of the \u03b3-secretase component nicastrin","volume":"111","author":"Xie","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189386_bb0135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cell.2020.11.049","article-title":"Structural basis of \u03b3-secretase inhibition and modulation by small molecule drugs","volume":"184","author":"Yang","year":"2021","journal-title":"Cell"},{"issue":"27","key":"10.1016\/j.bbcan.2025.189386_bb0140","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1021\/acs.biochem.9b00401","article-title":"Structure and function of the \u03b3-secretase complex","volume":"58","author":"Wolfe","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbcan.2025.189386_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.119007","article-title":"\u03b3-Secretase inhibitors for breast cancer and hepatocellular carcinoma: from mechanism to treatment","volume":"268","author":"Jia","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2019.07.004","article-title":"Substrate recognition and processing by \u03b3-secretase","volume":"1862","author":"Wolfe","year":"2020","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.bbcan.2025.189386_bb0155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.semcdb.2020.04.008","article-title":"The dynamics of \u03b3-secretase and its substrates","volume":"105","author":"Hitzenberger","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"issue":"6428","key":"10.1016\/j.bbcan.2025.189386_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw0930","article-title":"Recognition of the amyloid precursor protein by human \u03b3-secretase","volume":"363","author":"Zhou","year":"2019","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.bbcan.2025.189386_bb0165","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1016\/j.molcel.2023.10.029","article-title":"The \u03b3-secretase substrate proteome and its role in cell signaling regulation","volume":"83","author":"Hou","year":"2023","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189386_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24098417","article-title":"Presenilin-1 (PSEN1) mutations: clinical phenotypes beyond Alzheimer\u2019s disease","volume":"24","author":"Yang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"25","key":"10.1016\/j.bbcan.2025.189386_bb0175","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1038\/sj.onc.1209397","article-title":"Functional characterization of novel presenilin-2 variants identified in human breast cancers","volume":"25","author":"M.D. To","year":"2006","journal-title":"Oncogene"},{"issue":"34","key":"10.1016\/j.bbcan.2025.189386_bb0180","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2409343121","article-title":"Cortical neurodegeneration caused by Psen1 mutations is independent of a\u03b2","volume":"121","author":"Yan","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-025-00832-1","article-title":"Spectrum of \u03b3-secretase dysfunction as a unifying predictor of ADAD age at onset across PSEN1, PSEN2 and APP causal genes","volume":"20","author":"Fern\u00e1ndez","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bbcan.2025.189386_bb0190","article-title":"miR-27-3p enhances the sensitivity of triple-negative breast cancer cells to the antitumor agent Olaparib by targeting PSEN-1, the catalytic subunit of \u0393-secretase","volume":"11","author":"Zhao","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0195","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1186\/s12885-022-10383-z","article-title":"Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer","volume":"22","author":"Yousefi","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2025.189386_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107429","article-title":"Melatonin increases Olaparib sensitivity and suppresses cancer-associated fibroblast infiltration via suppressing the LAMB3-CXCL2 axis in TNBC","volume":"209","author":"Lai","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189386_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115051","article-title":"TRPS1 drives heterochromatic origin refiring and cancer genome evolution","volume":"43","author":"Yang","year":"2024","journal-title":"Cell Rep."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189386_bb0210","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.18632\/oncotarget.2291","article-title":"A central role for TRPS1 in the control of cell cycle and cancer development","volume":"5","author":"Wu","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0215","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41418-024-01271-z","article-title":"Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of \u0394Np63\u03b1 expression and promote breast cancer metastasis independent of HIF1\u03b1","volume":"31","author":"Chen","year":"2024","journal-title":"Cell Death Differ."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0220","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2024.03.006","article-title":"Genetic interactions reveal distinct biological and therapeutic implications in breast cancer","volume":"42","author":"Lin","year":"2024","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.bbcan.2025.189386_bb0225","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2011.39.3769","article-title":"Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial","volume":"30","author":"Bonanni","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188379","article-title":"Therapeutic aspects of AMPK in breast cancer: progress, challenges, and future directions","volume":"1874","author":"Ponnusamy","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0235","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41416-020-01137-4","article-title":"Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer","volume":"124","author":"Tailor","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0240","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0245","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-022-01302-6","article-title":"Phosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis","volume":"8","author":"Dong","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189386_bb0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12935-020-01172-4","article-title":"Effect of nicastrin on hepatocellular carcinoma proliferation and apoptosis through PI3K\/AKT signalling pathway modulation","volume":"20","author":"Wang","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0255","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: from mechanistic insights to targeted therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0260","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13046-023-02617-0","article-title":"Correction: NCSTN promotes hepatocellular carcinoma cell growth and metastasis via \u03b2-catenin activation in a Notch1\/AKT dependent manner","volume":"42","author":"Li","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189386_bb0265","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.7150\/ijbs.87334","article-title":"The critical role of \u03b3-secretase and its inhibitors in cancer and cancer therapeutics","volume":"19","author":"Song","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0270","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0275","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","article-title":"Wnt\/\u03b2-catenin signaling in cancers and targeted therapies","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189386_bb0280","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1111\/febs.15701","article-title":"Multifunctional intracellular matrix metalloproteinases: implications in disease","volume":"288","author":"Bassiouni","year":"2021","journal-title":"FEBS J."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189386_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061292","article-title":"Targeting BCL-2 in cancer: advances, challenges, and perspectives","volume":"13","author":"Hafezi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0290","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jnr.20203","article-title":"Functional reconstitution of gamma-secretase through coordinated expression of presenilin, nicastrin, Aph-1, and pen-2","volume":"77","author":"Periz","year":"2004","journal-title":"J. Neurosci. Res."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189386_bb0295","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41580-020-0227-y","article-title":"Cellular adaptation to hypoxia through hypoxia inducible factors and beyond","volume":"21","author":"Lee","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189386_bb0300","doi-asserted-by":"crossref","first-page":"10873","DOI":"10.1074\/jbc.M608856200","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation","volume":"282","author":"Zhang","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0305","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41594-024-01439-8","article-title":"Structural basis of human \u03b3-secretase inhibition by anticancer clinical compounds","volume":"23","author":"Guo","year":"2024","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189386_bb0310","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1021\/acs.jcim.3c01993","article-title":"Understanding the modulatory role of E2012 on the \u03b3-secretase-substrate interaction","volume":"64","author":"Guzm\u00e1n-Ocampo","year":"2024","journal-title":"J. Chem. Inf. Model."},{"issue":"30","key":"10.1016\/j.bbcan.2025.189386_bb0315","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1021\/bi0005456","article-title":"L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity","volume":"39","author":"Shearman","year":"2000","journal-title":"Biochemistry"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189386_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103652","article-title":"CRISPR-Cas9 in Alzheimer\u2019s disease: therapeutic trends, modalities, and challenges","volume":"28","author":"Chacko","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0325","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12575-021-00151-x","article-title":"Review of applications of CRISPR-Cas9 gene-editing technology in cancer research","volume":"23","author":"Zhao","year":"2021","journal-title":"Biol. Proc. Online"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189386_bb0330","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/iovs.63.10.14","article-title":"RO4929097, a selective \u03b3-secretase inhibitor, inhibits subretinal fibrosis via suppressing Notch and ERK1\/2 signaling in laser-induced mouse model","volume":"63","author":"Zhang","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189386_bb0335","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-21-3874","article-title":"A phase Ib\/II randomized study of RO4929097, a gamma-secretase or Notch inhibitor with or without Vismodegib, a hedgehog inhibitor, in advanced sarcoma","volume":"28","author":"Gounder","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189386_bb0340","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/neuros\/nyaa412","article-title":"A phase II and pharmacodynamic trial of RO4929097 for patients with recurrent\/progressive glioblastoma","volume":"88","author":"Peereboom","year":"2021","journal-title":"Neurosurgery"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189386_bb0345","first-page":"2507","article-title":"Combination therapy of a PSEN1-selective \u03b3-secretase inhibitor with dexamethasone and an XPO1 inhibitor to target T-cell acute lymphoblastic leukemia","volume":"108","author":"Vandersmissen","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.bbcan.2025.189386_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123034","article-title":"Regulating tumor cells to awaken T cell antitumor function and enhance melanoma immunotherapy","volume":"316","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189386_bb0355","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1021\/acsptsci.3c00099","article-title":"\u03b3-Secretase inhibitor potentiates the activity of Suberoylanilide hydroxamic acid by inhibiting its ability to induce epithelial to mesenchymal transition and Stemness via Notch pathway activation in triple-negative breast cancer cells","volume":"6","author":"Sen","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0360","article-title":"Gp130-dependent STAT3 activation in M-CSF-derived macrophages exaggerates tumor progression","volume":"11","author":"Xu","year":"2024","journal-title":"Genes Dis."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189386_bb0365","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ejca.2012.02.056","article-title":"A phase II study of RO4929097 in metastatic colorectal cancer","volume":"48","author":"Strosberg","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0370","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10637-014-0083-8","article-title":"A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma","volume":"32","author":"De Jesus-Acosta","year":"2014","journal-title":"Investig. New Drugs"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0375","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/cncr.29055","article-title":"Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933","volume":"121","author":"Lee","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189386_bb0380","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2015.03.005","article-title":"A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret, Chicago and California phase II consortia","volume":"137","author":"Diaz-Padilla","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"19","key":"10.1016\/j.bbcan.2025.189386_bb0385","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2011.36.8282","article-title":"Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors","volume":"30","author":"Tolcher","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.bbcan.2025.189386_bb0390","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/1078-0432.CCR-16-0048","article-title":"Molecular and clinical effects of Notch inhibition in glioma patients: a phase 0\/I trial","volume":"22","author":"Xu","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0395","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11060-016-2263-1","article-title":"Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma","volume":"130","author":"Pan","year":"2016","journal-title":"J. Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189386_bb0400","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clbc.2021.10.013","article-title":"A phase Ib dose escalation trial of RO4929097 (a \u03b3-secretase inhibitor) in combination with exemestane in patients with ER + metastatic breast cancer (MBC)","volume":"22","author":"Means-Powell","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bbcan.2025.189386_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101669","article-title":"NOTCH pathway inactivation reprograms stem-like oral cancer cells to JAK-STAT dependent state and provides the opportunity of synthetic lethality","volume":"32","author":"Ghosh","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbcan.2025.189386_bb0410","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.13402","article-title":"Down-regulated NEDD4L facilitates tumor progression through activating Notch signaling in lung adenocarcinoma","volume":"10","author":"Lin","year":"2022","journal-title":"PeerJ"},{"issue":"19","key":"10.1016\/j.bbcan.2025.189386_bb0415","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189386_bb0420","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1158\/1535-7163.MCT-18-0804","article-title":"Loss of Notch1 activity inhibits prostate cancer growth and metastasis and sensitizes prostate cancer cells to antiandrogen therapies","volume":"18","author":"Rice","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189386_bb0425","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2017.495","article-title":"A phase I trial of the \u03b3-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma","volume":"118","author":"Cook","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.bbcan.2025.189386_bb0430","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.ejca.2015.06.115","article-title":"Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours","volume":"51","author":"Piha-Paul","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0435","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2015.12.011","article-title":"Sequential combination therapy of ovarian cancer with cisplatin and \u03b3-secretase inhibitor MK-0752","volume":"140","author":"Chen","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189386_bb0440","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/bjc.2014.497","article-title":"A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours","volume":"111","author":"Brana","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189386_bb0445","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1158\/1078-0432.CCR-11-3326","article-title":"Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors","volume":"19","author":"Schott","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189386_bb0450","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/10799893.2020.1825490","article-title":"Function and mechanism exploration of zinc finger protein 64 in lung adenocarcinoma cell growth and metastasis","volume":"41","author":"Jiang","year":"2021","journal-title":"J. Recept. Signal Transduct. Res."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0455","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbrc.2016.01.165","article-title":"Gamma-glutamylcyclotransferase promotes the growth of human glioma cells by activating Notch-Akt signaling","volume":"471","author":"Shen","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0460","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1158\/1535-7163.MCT-20-0654","article-title":"PLK1 and NOTCH positively correlate in melanoma and their combined inhibition results in synergistic modulations of key melanoma pathways","volume":"20","author":"Su","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189386_bb0465","doi-asserted-by":"crossref","first-page":"14691","DOI":"10.1007\/s00432-023-05269-x","article-title":"In vitro antineoplastic effects of MK0752 in HPV-positive head and neck squamous cell carcinoma","volume":"149","author":"Varatanovic","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189386_bb0470","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16122184","article-title":"Combined treatment of uterine Leiomyosarcoma with gamma secretase inhibitor MK-0752 and chemotherapeutic agents decreases cellular invasion and increases apoptosis","volume":"16","author":"Abedin","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189386_bb0475","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01784-20","article-title":"Induction of HOX genes by hepatitis C virus infection via impairment of histone H2A Monoubiquitination","volume":"95","author":"Kasai","year":"2021","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0480","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012627","article-title":"Nanog maintains stemness of Lkb1-deficient lung adenocarcinoma and prevents gastric differentiation","volume":"13","author":"Tong","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189386_bb0485","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","article-title":"Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma","volume":"38","author":"Even","year":"2020","journal-title":"Investig. New Drugs"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0490","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10637-020-00944-z","article-title":"Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer","volume":"39","author":"Azaro","year":"2021","journal-title":"Investig. New Drugs"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0495","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10637-021-01094-6","article-title":"A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors","volume":"39","author":"Azaro","year":"2021","journal-title":"Investig. New Drugs"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189386_bb0500","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10637-020-01001-5","article-title":"A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors","volume":"39","author":"Doi","year":"2021","journal-title":"Investig. New Drugs"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0505","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cncr.33188","article-title":"Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma","volume":"127","author":"Borthakur","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0510","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13046-024-03210-9","article-title":"Targeting cancer-associated fibroblasts\/tumor cells cross-talk inhibits intrahepatic cholangiocarcinoma progression via cell-cycle arrest","volume":"43","author":"Mancarella","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189386_bb0515","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189386_bb0520","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.3168\/jds.2014-8222","article-title":"Presynchronization using a modified Ovsynch protocol or a single gonadotropin-releasing hormone injection 7 d before an Ovsynch-56 protocol for submission of lactating dairy cows to first timed artificial insemination","volume":"97","author":"Carvalho","year":"2014","journal-title":"J. Dairy Sci."},{"issue":"22","key":"10.1016\/j.bbcan.2025.189386_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225320","article-title":"Optimization of a three-dimensional culturing method for assessing the impact of cisplatin on Notch signaling in head and neck squamous cell carcinoma (HNSCC)","volume":"15","author":"Anameri\u00e7","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0530","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/1541-7786.MCR-19-0470","article-title":"Epigenetic profiling identifies LIF as a super-enhancer-controlled regulator of stem cell-like properties in osteosarcoma","volume":"18","author":"Lu","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189386_bb0535","first-page":"4121","article-title":"Reversing effect of NOTCH1 inhibitor LY3039478 on drug-resistance cells SGC7901\/DDP of human gastric cancer and its mechanism","volume":"22","author":"Wang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0540","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41594-024-01439-8","article-title":"Structural basis of human \u03b3-secretase inhibition by anticancer clinical compounds","volume":"32","author":"Guo","year":"2025","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189386_bb0545","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41419-022-05133-9","article-title":"AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling","volume":"13","author":"Ferrarotto","year":"2022","journal-title":"Cell Death Dis."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189386_bb0550","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-18-1635","article-title":"Rethinking gamma-secretase inhibitors for treatment of non-small-cell lung cancer: is Notch the target?","volume":"24","author":"Pine","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189386_bb0555","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1158\/1535-7163.MCT-17-0439","article-title":"Gamma secretase inhibition by BMS-906024 enhances efficacy of paclitaxel in lung adenocarcinoma","volume":"16","author":"Morgan","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189386_bb0560","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood.2020010463","article-title":"TLR8 gain of function: a tall surprise","volume":"137","author":"Boisson","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189386_bb0565","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s10637-018-0597-6","article-title":"A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours","volume":"36","author":"Aung","year":"2018","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bbcan.2025.189386_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2015.11.021","article-title":"A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer","volume":"56","author":"Pant","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189386_bb0575","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-secretase inhibitor for Desmoid tumors","volume":"388","author":"Gounder","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189386_bb0580","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.80","article-title":"A phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma","volume":"5","author":"Papayannidis","year":"2015","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0585","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","article-title":"A phase I, dose-finding study in patients with advanced solid malignancies of the oral \u03b3-secretase inhibitor PF-03084014","volume":"21","author":"Messersmith","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0590","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/leu.2014.143","article-title":"The \u03b3-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells","volume":"29","author":"L\u00f3pez-Guerra","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189386_bb0595","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1158\/1535-7163.MCT-17-0001","article-title":"Notch inhibitor PF-03084014 inhibits hepatocellular carcinoma growth and metastasis via suppression of cancer stemness due to reduced activation of Notch1-Stat3","volume":"16","author":"Wu","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189386_bb0600","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1158\/1078-0432.CCR-15-0242","article-title":"Notch pathway inhibition using PF-03084014, a \u03b3-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer","volume":"21","author":"Cui","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189386_bb0605","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1158\/1078-0432.CCR-14-1348","article-title":"PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a \u03b3-secretase inhibitor","volume":"21","author":"Wang","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189386_bb0610","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2217\/fon-2020-1269","article-title":"Belantamab mafodotin in combination with novel agents in relapsed\/refractory multiple myeloma: DREAMM-5 study design","volume":"17","author":"Nooka","year":"2021","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0615","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40035-021-00235-4","article-title":"Pharmacological inhibition of asparaginyl endopeptidase by \u03b4-secretase inhibitor 11 mitigates Alzheimer's disease-related pathologies in a senescence-accelerated mouse model","volume":"10","author":"Wang","year":"2021","journal-title":"Transl. Neurodegener."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189386_bb0620","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-024-02002-x","article-title":"Nirogacestat: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.bbcan.2025.189386_bb0625","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/PO.21.00228","article-title":"Response of NOTCH1-activated tracheal adenoid cystic carcinoma to the gamma secretase inhibitor Nirogacestat","volume":"5","author":"Kieran","year":"2021","journal-title":"JCO Precis. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189386_bb0630","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41419-021-03836-z","article-title":"Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the \u03b3-secretase complex","volume":"12","author":"Weir","year":"2021","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041098","article-title":"Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture","volume":"19","author":"Usui","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189386_bb0640","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1074\/jbc.RA119.007671","article-title":"A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting \u03b3-secretase-mediated activation of Notch signaling","volume":"294","author":"Das","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189386_bb0645","doi-asserted-by":"crossref","first-page":"6000","DOI":"10.1038\/srep06000","article-title":"Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells","volume":"4","author":"Horinaka","year":"2014","journal-title":"Sci. Rep."},{"issue":"22","key":"10.1016\/j.bbcan.2025.189386_bb0650","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41388-023-02692-9","article-title":"Novel thrombospondin-1 transcript exhibits distinctive expression and activity in thyroid tumorigenesis","volume":"42","author":"Hong","year":"2023","journal-title":"Oncogene"},{"issue":"21","key":"10.1016\/j.bbcan.2025.189386_bb0655","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.4161\/cbt.8.21.9803","article-title":"Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells","volume":"8","author":"Soundararajan","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbcan.2025.189386_bb0660","article-title":"Celecoxib and sulindac sulfide elicit anticancer effects on PIK3CA-mutated head and neck cancer cells through endoplasmic reticulum stress, reactive oxygen species, and mitochondrial dysfunction","volume":"224","author":"Nguyen","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0665","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-021-01114-1","article-title":"PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia","volume":"14","author":"Govaerts","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0670","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/jcp.29232","article-title":"Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin","volume":"235","author":"Zhang","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0675","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/bcr2347","article-title":"The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition","volume":"11","author":"Han","year":"2009","journal-title":"Breast Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189386_bb0680","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1601-0825.2006.01334.x","article-title":"Gamma-secretase inhibitors exerts antitumor activity via down-regulation of Notch and nuclear factor kappa B in human tongue carcinoma cells","volume":"13","author":"Yao","year":"2007","journal-title":"Oral Dis."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189386_bb0685","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/1541-7786.MCR-17-0058","article-title":"Synergistic activity with NOTCH inhibition and androgen ablation in ERG-positive prostate cancer cells","volume":"15","author":"Mohamed","year":"2017","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189386_bb0690","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.50","article-title":"GSI-I (Z-LLNle-CHO) inhibits \u03b3-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia","volume":"25","author":"Meng","year":"2011","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189386_bb0695","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1593\/neo.121888","article-title":"PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis","volume":"15","author":"Marshall","year":"2013","journal-title":"Neoplasia"},{"issue":"19","key":"10.1016\/j.bbcan.2025.189386_bb0700","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1158\/0008-5472.CAN-21-0524","article-title":"Targeting Notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity","volume":"81","author":"Sabol","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189386_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2021.114057","article-title":"Cimicifuga dahurica extract inhibits the proliferation, migration and invasion of breast cancer cells MDA-MB-231 and MCF-7 in vitro and in vivo","volume":"277","author":"Jia","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bbcan.2025.189386_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105686","article-title":"Cimigenoside functions as a novel \u03b3-secretase inhibitor and inhibits the proliferation or metastasis of human breast cancer cells by \u03b3-secretase\/Notch axis","volume":"169","author":"Jia","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2025.189386_bb0715","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jep.2017.07.040","article-title":"Traditional uses, phytochemistry, pharmacology and toxicology of the genus Cimicifuga: a review","volume":"209","author":"Guo","year":"2017","journal-title":"J. Ethnopharmacol."},{"issue":"Pt 2","key":"10.1016\/j.bbcan.2025.189386_bb0720","article-title":"Activation of the \u03b3-secretase\/NICD-PXR\/Notch pathway induces Taxol resistance in triple-negative breast cancer","volume":"230","author":"Wang","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189386_bb0725","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189386_bb0730","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-019-00337-6","article-title":"CDK4\/6 inhibitors expand the therapeutic options in breast cancer: Palbociclib, Ribociclib and Abemaciclib","volume":"33","author":"Eggersmann","year":"2019","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0735","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1186\/s12885-024-12974-4","article-title":"Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study","volume":"24","author":"Ran","year":"2024","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189386_bb0740","doi-asserted-by":"crossref","first-page":"78","DOI":"10.31083\/j.fbl2902078","article-title":"The large ectodomain of APP prevents APP from being directly cleaved by \u03b3-secretase","volume":"29","author":"Li","year":"2024","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189386_bb0745","doi-asserted-by":"crossref","first-page":"618","DOI":"10.34172\/apb.2021.070","article-title":"DR-5 and DLL-4 mAb functionalized SLNs of gamma-secretase inhibitors - an approach for TNBC treatment","volume":"11","author":"Kumari","year":"2021","journal-title":"Adv. Pharm. Bull."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189386_bb0750","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.3390\/curroncol31100437","article-title":"The experience of patients with endocrine therapy for breast cancer: a patient journey map based on qualitative research","volume":"31","author":"Yao","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bbcan.2025.189386_bb0755","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.897984","article-title":"Case report: individualized treatment of advanced breast cancer with the use of the patient-derived tumor-like cell cluster model","volume":"12","author":"Xia","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189386_bb0760","article-title":"An overview about biomarkers in breast cancer: insights into the diagnostic and prognostic significance","volume":"567","author":"Santos","year":"2025","journal-title":"Clin. Chim. Acta"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189386_bb0765","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/s41416-024-02879-1","article-title":"A proteome-wide association study identifies putative causal proteins for breast cancer risk","volume":"131","author":"Zhao","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189386_bb0770","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41392-022-01040-9","article-title":"Low-dose metformin and PEN2-dependent lysosomal AMPK activation: benefits outnumber side effects","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7899","key":"10.1016\/j.bbcan.2025.189386_bb0775","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-022-04431-8","article-title":"Low-dose metformin targets the lysosomal AMPK pathway through PEN2","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"},{"issue":"28","key":"10.1016\/j.bbcan.2025.189386_bb0780","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/s41388-023-02737-z","article-title":"A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer","volume":"42","author":"Meng","year":"2023","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189386_bb0785","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25001283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:51:28Z","timestamp":1761943888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25001283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":157,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0304419X25001283"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189386","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Key subunits of \u03b3-secretase complex and breast cancer progression: biological function, regulation mode and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189386"}}